Clinical Trial Participant Discusses Approval of New Myeloma Treatment From a Patient Perspective

Description: The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Patient Power Founder Andrew Schorr caught with patient #1 in the elotuzumab trial, Jay Carty, to get his thoughts on the approval and his perspective on the future of myeloma treatment.

Get email alerts | http://www.patientpower.inf...

Subscribe on YouTube |
Like on Facebook |
Follow on Twitter |
Follow on Google+ |
Shared By : P2Professional
Posted on : 12/03/15
Added : 4 years ago